Phase III clinical trial - Sein métastatique RH+

AMBRE
Sein métastatique RH+
Ouvert depuis le: 09.28.2021
Site: Paris
Ouvert depuis le: 02.24.2021
Site: Saint-Cloud
Public cible
Adulte
OPEN-LABEL, RANDOMIZED, MULTICENTER, PHASE III STUDY, COMPARING;STANDARD CHEMOTHERAPY TO ENDOCRINE THERAPY + ABEMACICLIB;COMBINATION AS INITIAL METASTATIC TREATMENT AMONG PATIENTS WITH;VISCERAL METASTASIS OF ER+ HER2- BREAST CANCER, HIGH BURDEN;DISEASE
Description de l'essai

AMBRE is a phase III study comparing two standard treatments as initial metastatic treatment in ER+/HER2- breast cancer (BC) patients with visceral metastasis and high burden disease: Chemotherapy and combination of endocrine therapy with abemaciclib.